Calcimedica reports 2024 financial results and provides clinical & corporate updates

Enrollment ongoing in phase 2 kourage trial of auxora™ in acute kidney injury (aki) and respiratory failure; data expected around the end of 2025 post-hoc analysis of subset of patients with aki in the phase 2 cardea trial of auxora in severe covid-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with auxora versus placebo cash position expected to fund operations into mid-2026 la jolla, calif. , march 27, 2025 /prnewswire/ -- calcimedica inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended december 31, 2024 and provided clinical and corporate updates.
CALC Ratings Summary
CALC Quant Ranking